Questions, Questions for Donanemab, Lecanemab
As immunotherapies enter care, scientists explore when to stop them, how amyloid removal relates to cognitive benefit, and whether fluid markers will track both plaque and tangles responses.
As immunotherapies enter care, scientists explore when to stop them, how amyloid removal relates to cognitive benefit, and whether fluid markers will track both plaque and tangles responses.
At AAIC 2024, speakers pointed to worsening biomarkers and cognition after dosing stopped, and linked the protofibrils targeted by lecanemab to neurodegeneration.
Plaques and their surrounding cells and neurites occupy 6 percent of cortical volume. Their removal could account for shrinkage during amyloid immunotherapy.
At AAIC, scientists linked Alzheimer’s pathology to the demise of nearby neurons, and implicated plaque-adjacent glia in sparking tau pathology.
Alzheimer’s markers are quantifiable in dried plasma, simplifying future diagnoses. With new ultrasensitive assays, hundreds of proteins could be analyzed this way.
Markers for AD can be measured in dried blood. This could greatly simplify diagnosis in far-flung areas. With new ultrasensitive assays, hundreds of proteins could be tested this way.
The percentage of tau fragments phosphorylated at amino acid 217 best pegged people with brain amyloid or tangles. The ratio’s edge over other markers is slight, though.
An expert panel has laid out performance standards on amyloid tests. Clinical context will dictate accuracy, and online calculators might help.
New in last 7 days
Latest Comments